These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

282 related items for PubMed ID: 20663492

  • 1. Quality of T-cells after stimulation with leukemia-derived dendritic cells (DC) from patients with acute myeloid leukemia (AML) or myeloid dysplastic syndrome (MDS) is predictive for their leukemia cytotoxic potential.
    Liepert A, Grabrucker C, Kremser A, Dreyssig J, Ansprenger C, Freudenreich M, Kroell T, Reibke R, Tischer J, Schweiger C, Schmid C, Kolb HJ, Schmetzer H.
    Cell Immunol; 2010; 265(1):23-30. PubMed ID: 20663492
    [Abstract] [Full Text] [Related]

  • 2. The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells.
    Grabrucker C, Liepert A, Dreyig J, Kremser A, Kroell T, Freudenreich M, Schmid C, Schweiger C, Tischer J, Kolb HJ, Schmetzer H.
    J Immunother; 2010 Jun; 33(5):523-37. PubMed ID: 20463595
    [Abstract] [Full Text] [Related]

  • 3. Dendritic cells (DCs) can be successfully generated from leukemic blasts in individual patients with AML or MDS: an evaluation of different methods.
    Kremser A, Dressig J, Grabrucker C, Liepert A, Kroell T, Scholl N, Schmid C, Tischer J, Kufner S, Salih H, Kolb HJ, Schmetzer H.
    J Immunother; 2010 Jun; 33(2):185-99. PubMed ID: 20139775
    [Abstract] [Full Text] [Related]

  • 4. Antileukemic T-cell responses can be predicted by the composition of specific regulatory T-cell subpopulations.
    Schick J, Vogt V, Zerwes M, Kroell T, Kraemer D, Köhne CH, Hausmann A, Buhmann R, Tischer J, Schmetzer H.
    J Immunother; 2013 May; 36(4):223-37. PubMed ID: 23603857
    [Abstract] [Full Text] [Related]

  • 5. Leukaemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with myelodysplasia: a methodological approach under serum-free culture conditions.
    Kufner S, Zitzelsberger H, Kroell T, Pelka-Fleischer R, Salem A, de Valle F, Schmid C, Schweiger C, Kolb HJ, Schmetzer HM.
    Scand J Immunol; 2005 Jul; 62(1):75-85. PubMed ID: 16091127
    [Abstract] [Full Text] [Related]

  • 6. Profiles of activation, differentiation-markers, or β-integrins on T cells contribute to predict T cells' antileukemic responses after stimulation with leukemia-derived dendritic cells.
    Vogt V, Schick J, Ansprenger C, Braeu M, Kroell T, Kraemer D, Köhne CH, Hausmann A, Buhmann R, Tischer J, Schmetzer H.
    J Immunother; 2014 Jul; 37(6):331-47. PubMed ID: 24911794
    [Abstract] [Full Text] [Related]

  • 7. Leukemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with acute myeloid leukaemia: a methodological approach under serum-free culture conditions.
    Kufner S, Zitzelsberger H, Kroell T, Pelka-Fleischer R, Salem A, de Valle F, Schweiger C, Nuessler V, Schmid C, Kolb HJ, Schmetzer HM.
    Scand J Immunol; 2005 Jul; 62(1):86-98. PubMed ID: 16091128
    [Abstract] [Full Text] [Related]

  • 8. Clinical grade expansion of CD45RA, CD45RO, and CD62L-positive T-cell lines from HLA-compatible donors: high cytotoxic potential against AML and ALL cells.
    Barbui AM, Borleri G, Conti E, Ciocca A, Salvi A, Micò C, Introna M, Rambaldi A.
    Exp Hematol; 2006 Apr; 34(4):475-85. PubMed ID: 16569594
    [Abstract] [Full Text] [Related]

  • 9. CTLA-4 blockade by a human MAb enhances the capacity of AML-derived DC to induce T-cell responses against AML cells in an autologous culture system.
    Zhong RK, Loken M, Lane TA, Ball ED.
    Cytotherapy; 2006 Apr; 8(1):3-12. PubMed ID: 16627340
    [Abstract] [Full Text] [Related]

  • 10. Improved effector function of leukemia-specific T-lymphocyte clones trained with AML-derived dendritic cells.
    Schuster FR, Buhmann R, Reuther S, Hubner B, Grabrucker C, Liepert A, Reibke R, Lichtner P, Yang T, Kroell T, Kolb HJ, Borkhardt A, Schmetzer H.
    Cancer Genomics Proteomics; 2008 Apr; 5(5):275-86. PubMed ID: 19129558
    [Abstract] [Full Text] [Related]

  • 11. Serum-free generation and quantification of functionally active Leukemia-derived DC is possible from malignant blasts in acute myeloid leukemia and myelodysplastic syndromes.
    Kufner S, Fleischer RP, Kroell T, Schmid C, Zitzelsberger H, Salih H, de Valle F, Treder W, Schmetzer HM.
    Cancer Immunol Immunother; 2005 Oct; 54(10):953-70. PubMed ID: 15789235
    [Abstract] [Full Text] [Related]

  • 12. Activation of autologous leukemia-specific T cells in acute myeloid leukemia: monocyte-derived dendritic cells cocultured with leukemic blasts compared with leukemia-derived dendritic cells.
    Draube A, Beyer M, Wolf J.
    Eur J Haematol; 2008 Oct; 81(4):281-8. PubMed ID: 18573171
    [Abstract] [Full Text] [Related]

  • 13. Generation of T-cell lines to autologous acute myeloid leukemia cells by competitive limiting dilution culture of acute myeloid leukemia mononuclear cells.
    Zhong RK, Lane TA, Ball ED.
    Exp Hematol; 2008 Apr; 36(4):486-94. PubMed ID: 18249062
    [Abstract] [Full Text] [Related]

  • 14. Various 'dendritic cell antigens' are already expressed on uncultured blasts in acute myeloid leukemia and myelodysplastic syndromes.
    Dreyssig J, Kremser A, Liepert A, Grabrucker C, Freudenreich M, Schmid C, Kroell T, Scholl N, Tischer J, Kufner S, Salih H, Kolb HJ, Schmetzer HM.
    Immunotherapy; 2011 Sep; 3(9):1113-24. PubMed ID: 21913833
    [Abstract] [Full Text] [Related]

  • 15. [T-cell immunity against autologous leukemic cell mediated by in vitro bone marrow-derived dendritic cell from patients with acute myeloid leukemia in complete remission].
    He X, You S, Bian S.
    Zhonghua Xue Ye Xue Za Zhi; 2001 Dec; 22(12):629-32. PubMed ID: 16200709
    [Abstract] [Full Text] [Related]

  • 16. Cytokine Release Patterns in Mixed Lymphocyte Culture (MLC) of T-Cells with Dendritic Cells (DC) Generated from AML Blasts Contribute to Predict anti-Leukaemic T-Cell Reactions and Patients' Response to Immunotherapy.
    Fischbacher D, Merle M, Liepert A, Grabrucker C, Kroell T, Kremser A, Dreyßig J, Freudenreich M, Schuster F, Borkhardt A, Kraemer D, Koehne CH, Kolb HJ, Schmid C, Schmetzer HM.
    Cell Commun Adhes; 2015 Dec; 22(2-6):49-65. PubMed ID: 27602789
    [Abstract] [Full Text] [Related]

  • 17. Leukemia-specific T-cell reactivity induced by leukemic dendritic cells is augmented by 4-1BB targeting.
    Houtenbos I, Westers TM, Dijkhuis A, de Gruijl TD, Ossenkoppele GJ, van de Loosdrecht AA.
    Clin Cancer Res; 2007 Jan 01; 13(1):307-15. PubMed ID: 17170077
    [Abstract] [Full Text] [Related]

  • 18. [Induction of efficient T-cell immunity against autologous leukemia cells by dendritic cells pulsed with the leukemia cell total RNA].
    Ge W, You SG, Wang YF, Li CH, Liu XF, He XP, Ma S, Qiu L.
    Zhonghua Xue Ye Xue Za Zhi; 2005 Aug 01; 26(8):461-4. PubMed ID: 16383235
    [Abstract] [Full Text] [Related]

  • 19. Optimization of the concentration of autologous serum for generation of leukemic dendritic cells from acute myeloid leukemic cells for clinical immunotherapy.
    Choi BH, Kang HK, Park JS, Kim SK, Pham TN, Zhu XW, Cho D, Nam JH, Chung IJ, Kim YJ, Rhee JH, Kim HJ, Lee JJ.
    J Clin Apher; 2006 Dec 01; 21(4):233-40. PubMed ID: 17120232
    [Abstract] [Full Text] [Related]

  • 20. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts.
    Li L, Giannopoulos K, Reinhardt P, Tabarkiewicz J, Schmitt A, Greiner J, Rolinski J, Hus I, Dmoszynska A, Wiesneth M, Schmitt M.
    Int J Oncol; 2006 Apr 01; 28(4):855-61. PubMed ID: 16525634
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.